A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13

Clinical trial NCT05934890 · UNKNOWN

Trial details

NCT number: NCT05934890
Sponsor: Walvax Biotechnology Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Pneumococcal Disease, Invasive

Start date: 2023-11-23
Primary completion: 2025-03-01
Enrollment: 630

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.